Moderna (MRNA) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow ...

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market ...

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna shares gained 48% in June as investors rotated out of artificial-intelligence stocks. (Graham Hughes/Bloomberg) ...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European ...

Moderna (MRNA) climbed to $81.42, up 169% annually. Analysts set average target at $37 while insiders sold $6.1M worth of ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Global health organisation CEPI will give roughly $60 million to Moderna and two other groups to accelerate the development of shots ​against Ebola Bundibugyo, the deadly virus that has swept through ...

Moderna announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. He will also join ...